Whalesbook
ICICI Securities ki forecast kya hai?
Dekho, ICICI Securities ka kehna hai ki is quarter mein net profit 34.8% badh ke ₹60.5 crore ho sakta hai, aur net sales bhi 23.2% upar jaake ₹425.4 crore tak pahunch sakti hai. EBITDA bhi 35.8% badhne ka forecast hai. Abhi stock price around ₹472.2 chal raha hai aur market cap ₹9,800 crore ke aas paas hai. Lekin ek interesting baat ye hai ki stock ₹397.08 se ₹565.75 tak bhi gaya hai pichle 52 hafte mein, matlab investors thode cautious hain ki ye rapid growth kitni sustainable hai.
Diagnostics Sector toh boom kar raha hai!
Waise bhi, India ka diagnostics sector ekdum full speed mein hai. ₹1.1 lakh crore tak pahunchne ka estimate hai 2026 tak, aur isme Metropolis jaise companies ka bada role hai. Q4 mein inki consolidated revenue 23% tak badh sakti hai. Analyst log bhi keh rahe hain ki 'Buy' karna chahiye aur average target price ₹563.39 de rahe hain, matlab lagbhag 18% ka potential upside dikh raha hai.
Par Valuation ka scene kya hai?
Ab aate hain asli point par, yaani valuation ki chinta. Market toh badh raha hai aur analysts buy rating de rahe hain, par competition bahut hai. Inka sabse bada rival, Dr. Lal PathLabs, aksar better results dikhata hai, especially profit growth mein. Dr. Lal PathLabs ne pichle saal ₹24.0 per share ka dividend diya, jabki Metropolis ne zero! Aur valuation? Metropolis ka P/E ratio 55.50 se 72.79 ke beech hai, jabki Dr. Lal PathLabs ka P/E sirf 22.0x hai. Ye ek bada difference hai, aur market soch raha hai ki kya Metropolis ka historical performance is premium valuation ko justify karta hai?
Pichhle record aur risks
Pichhle 5 saalon ka record dekho toh Metropolis ki performance utni consistent nahi rahi hai. Sales growth sirf 9.22% thi, aur earnings toh average -8.2% gir rahi thi saal dar saal. Haalat sudhri hai, pichle saal earnings 10.5% badhi thi, par phir bhi, high P/E aur dividend na dena, Dr. Lal PathLabs jaise competitors ke saamne inko thoda alag banata hai. Aur haan, 2022 ke end mein kuch tax proceedings bhi thi, jiska operational impact nahi bataya gaya, par ye management par scrutiny badha deta hai. Inka return on equity 11.7% aur net profit margins 10.7% bhi sector average se kam hain.
Future prospects kaise hain?
Toh overall, Q4 ke numbers aur sector trends short term mein achhe lag rahe hain. Par Metropolis ka future is baat par depend karta hai ki woh competition mein apni operational efficiency kaise sudharte hain aur valuation gap kaise kam karte hain. Kuch analysts 42% tak ka upside bhi dekh rahe hain. Q4 mein 14.5% organic aur 23% consolidated growth achha sign hai. Par investors ko competition aur past inconsistencies ko dhyan mein rakhna hoga. B2C segment ko badhana aur acquisitions ko manage karna diagnostics market mein aagey badhne ke liye crucial hoga.